BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33063439)

  • 1. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a secondary analysis of the PITCHES trial.
    Fleminger J; Seed PT; Smith A; Juszczak E; Dixon PH; Chambers J; Dorling J; Williamson C; Thornton JG; Chappell LC
    BJOG; 2021 May; 128(6):1066-1075. PubMed ID: 33063439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES).
    Chappell LC; Chambers J; Dixon PH; Dorling J; Hunter R; Bell JL; Bowler U; Hardy P; Juszczak E; Linsell L; Rounding C; Smith A; Williamson C; Thornton JG
    Trials; 2018 Nov; 19(1):657. PubMed ID: 30482254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
    Chappell LC; Bell JL; Smith A; Linsell L; Juszczak E; Dixon PH; Chambers J; Hunter R; Dorling J; Williamson C; Thornton JG;
    Lancet; 2019 Sep; 394(10201):849-860. PubMed ID: 31378395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    Vasavan T; Deepak S; Jayawardane IA; Lucchini M; Martin C; Geenes V; Yang J; Lövgren-Sandblom A; Seed PT; Chambers J; Stone S; Kurlak L; Dixon PH; Marschall HU; Gorelik J; Chappell L; Loughna P; Thornton J; Pipkin FB; Hayes-Gill B; Fifer WP; Williamson C
    J Hepatol; 2021 May; 74(5):1087-1096. PubMed ID: 33276032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial.
    Chappell LC; Gurung V; Seed PT; Chambers J; Williamson C; Thornton JG;
    BMJ; 2012 Jun; 344():e3799. PubMed ID: 22695903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy course in patients with intrahepatic cholestasis of pregnancy treated with very low doses of ursodeoxycholic acid.
    Grymowicz M; Czajkowski K; Smolarczyk R
    Scand J Gastroenterol; 2016 Jan; 51(1):78-85. PubMed ID: 26152830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic cholestasis of pregnancy: observational study of the treatment with low-dose ursodeoxycholic acid.
    Joutsiniemi T; Timonen S; Linden M; Suvitie P; Ekblad U
    BMC Gastroenterol; 2015 Jul; 15():92. PubMed ID: 26215400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study.
    Manna LB; Ovadia C; Lövgren-Sandblom A; Chambers J; Begum S; Seed P; Walker I; Chappell LC; Marschall HU; Williamson C
    BJOG; 2019 Dec; 126(13):1633-1640. PubMed ID: 31483939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).
    Kong X; Kong Y; Zhang F; Wang T; Yan J
    Medicine (Baltimore); 2016 Oct; 95(40):e4949. PubMed ID: 27749550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid.
    Glantz A; Marschall HU; Lammert F; Mattsson LA
    Hepatology; 2005 Dec; 42(6):1399-405. PubMed ID: 16317669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy.
    Walker KF; Chappell LC; Hague WM; Middleton P; Thornton JG
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD000493. PubMed ID: 32716060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis.
    Roncaglia N; Locatelli A; Arreghini A; Assi F; Cameroni I; Pezzullo JC; Ghidini A
    BJOG; 2004 Jan; 111(1):17-21. PubMed ID: 14687046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe.
    Ambros-Rudolph CM; Glatz M; Trauner M; Kerl H; Müllegger RR
    Arch Dermatol; 2007 Jun; 143(6):757-62. PubMed ID: 17576942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience.
    Zapata R; Sandoval L; Palma J; Hernández I; Ribalta J; Reyes H; Sedano M; Tohá D; Silva JJ
    Liver Int; 2005 Jun; 25(3):548-54. PubMed ID: 15910492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of pharmacological treatment on selected parameters of intrahepatic cholestasis of pregnancy].
    Brzozowska M; Kowalska-Koprek U; Karowicz-Bilińska A
    Ginekol Pol; 2010 Feb; 81(2):94-8. PubMed ID: 20232705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy.
    Brites D; Rodrigues CM; Oliveira N; Cardoso M; Graça LM
    J Hepatol; 1998 Jan; 28(1):91-8. PubMed ID: 9537870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: Results in real-world conditions and factors predictive of response to treatment.
    Bacq Y; le Besco M; Lecuyer AI; Gendrot C; Potin J; Andres CR; Aubourg A
    Dig Liver Dis; 2017 Jan; 49(1):63-69. PubMed ID: 27825922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.
    Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjövall J
    Hepatology; 1997 Dec; 26(6):1573-9. PubMed ID: 9398000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis.
    Gümüş Güler B; Özler S
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):271-276. PubMed ID: 31919038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.
    Ovadia C; Seed PT; Sklavounos A; Geenes V; Di Ilio C; Chambers J; Kohari K; Bacq Y; Bozkurt N; Brun-Furrer R; Bull L; Estiú MC; Grymowicz M; Gunaydin B; Hague WM; Haslinger C; Hu Y; Kawakita T; Kebapcilar AG; Kebapcilar L; Kondrackienė J; Koster MPH; Kowalska-Kańka A; Kupčinskas L; Lee RH; Locatelli A; Macias RIR; Marschall HU; Oudijk MA; Raz Y; Rimon E; Shan D; Shao Y; Tribe R; Tripodi V; Yayla Abide C; Yenidede I; Thornton JG; Chappell LC; Williamson C
    Lancet; 2019 Mar; 393(10174):899-909. PubMed ID: 30773280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.